Eletriptan is indicated in adults for the acute treatment of the headache phase of migraine attacks, with or without aura.
For this indication, competent medicine agencies globally authorize below treatments:
For: Adults (18-64)
Oral, between 40 and 80 milligrams, daily, one dose.
Eletriptan tablets should be taken as early as possible after the onset of migraine headache but they are also effective if taken at a later stage during a migraine attack.
Eletriptan, if taken during the aura phase, has not been demonstrated to prevent migraine headache and therefore eletriptan should only be taken during the headache phase of migraine.
Eletriptan tablets should not be used prophylactically.
The recommended initial dose is 40 mg.
If headache returns within 24 hours: If the migraine headache recurs within 24 hours of an initial response, a second dose of the same strength of eletriptan has been shown to be effective in treating the recurrence. If a second dose is required, it should not be taken within 2 hours of the initial dose.
If no response is obtained: If a patient does not achieve a headache response to the first dose of eletriptan within 2 hours, a second dose should not be taken for the same attack as clinical trials have not adequately established efficacy with the second dose. Clinical trials show that patients who do not respond to the treatment of an attack are still likely to respond to the treatment of a subsequent attack.
Patients who do not obtain satisfactory efficacy after an appropriate trial of 40 mg, (e.g. good tolerability and failure to respond in 2 out of 3 attacks), may be effectively treated with 80 mg (2 × 40 mg) in subsequent migraine attacks. A second dose of 80 mg should not be taken within 24 hours.
The maximum daily dose should not exceed 80 mg.
The tablets should be swallowed whole with water.